Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2025-12-30 @ 8:47 PM
Study NCT ID:
NCT06868667
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-09
First Post:
2025-03-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-28
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-19
Completion Date Type:
ESTIMATED
First Submit Date:
2025-03-06
First Submit QC Date:
None
Study First Post Date:
2025-03-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-03
Results First Submit QC Date:
None
Results First Post Date:
2025-05-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-08
Last Update Post Date:
2025-05-09
Last Update Post Date Type:
ACTUAL